Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Feb;163(3-4):102-5.
doi: 10.1007/s10354-012-0166-0. Epub 2012 Dec 20.

Efficacy and safety of Echinaforce® in respiratory tract infections

Andreas Schapowal  1
Affiliations
Review

Efficacy and safety of Echinaforce® in respiratory tract infections

Andreas Schapowal. Wien Med Wochenschr. 2013 Feb.

Abstract
in English, German

Echinaforce® is the standardised extract of Echinacea purpurea from Bioforce, Switzerland. Recent studies show immunomodulation and broad antiviral effects against respiratory tract viruses. Haemagglutinin and Neuraminidase are blocked. In contrast to Oseltamivir no resistance is caused by Echinaforce®. A randomised, double-blind, placebo-controlled study over four months confirms that Echinaforce® supports the immune resistance and acts directly against a series of viruses. Echinaforce® is efficacious and safe in respiratory tract infections for long-term and short-term prevention as well as for acute treatment.

Echinaforce® ist der standardisierte Extrakt von Echinacea purpurea (Bioforce, Schweiz). Jüngste Studien zeigen eine Immunmodulation und breite antivirale Effekte gegen Atemwegsviren. Hä-magglutinin und Neuraminidase werden blockiert. Im Gegensatz zu Oseltamivir bewirkt Echinaforce® keine Resistenz. Eine randomisierte, plazbokontrollierte Doppelblindstudie über vier Monate bestätigt, dass Echinaforce® die Immunabwehr unterstützt und direkt gegen häufige Atemwegsviren wirkt. Echinaforce® ist bei Atemwegsinfekten effizient und sicher in der Langzeit- und Kurzzeit-Prävention, sowie in der Akutbehandlung.

PubMed Disclaimer

References

    1. Rotbart HA, Hayden FG. Picornavirus infections: a primer for the practitioner. Arch Fam Med. 2000;9(90):913–922. doi: 10.1001/archfami.9.9.913. - DOI - PubMed
    1. Fendrick AM. Viral respiratory infections due to rhinoviruses: current knowledge, new developments. Am J Ther. 2003;10:193–202. doi: 10.1097/00045391-200305000-00006. - DOI - PubMed
    1. Adams PF, Hendershot GE, Marano MA. Current estimates from the National Health Interview Survey 1996. In: Vital and Health Statistics Series 10. Data from the National Health Survey; 1999. pp. 1–203. - PubMed
    1. Fendrick AM, Monto AS, Nightengale B, Sarnes M. The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch Intern Med. 2003;163:487–494. doi: 10.1001/archinte.163.4.487. - DOI - PubMed
    1. Johnston SL. Problems and prospects of developing effective therapy for common cold viruses. Trends Microbiol. 1997;5(2):58–63. doi: 10.1016/S0966-842X(96)10082-2. - DOI - PMC - PubMed

MeSH terms